New multiple sclerosis (MS) 'wonder' drug Rituxan doesn't work, the manufacturer has admitted. A two-year study has discovered that it is no better than placebo in slowing disability among sufferers with primary progressive MS.
Had it worked, it would have been the third disease that Rituxan is supposed to treat. It was developed by its manufacturer Genentech and Biogen Idec as a drug for cancer of the blood, but it is now one of the most prescribed drugs for rheumatoid arthritis, with sales in the USA alone of $2.29bn last year.
(Source: New York Times, April 15, 2008).